Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies

Tariq I. Mughal, Saulius Girnius, Steven T. Rosen, Shaji K Kumar, Adrian Wiestner, Omar Abdel-Wahab, Jean Jacques Kiladjian, Wyndham H. Wilson, Richard A. Van Etten

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Over the past decade, there has been increasing biochemical evidence that the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is aberrantly activated in malignant cells from patients with a wide spectrum of cancers of the blood and immune systems. The emerging availability of small molecule inhibitors of JAK and other signaling molecules in the JAK/STAT pathway has allowed preclinical studies validating an important role of this pathway in the pathogenesis of many hematologic malignancies, and provided motivation for new strategies for treatment of these diseases. Here, a round-table panel of experts review the current preclinical and clinical landscape of the JAK/STAT pathway in acute lymphoid and myeloid leukemias, lymphomas and myeloma, and chronic myeloid neoplasms.

Original languageEnglish (US)
Pages (from-to)1968-1979
Number of pages12
JournalLeukemia and Lymphoma
Volume55
Issue number9
DOIs
StatePublished - 2014

Fingerprint

Janus Kinases
Hematologic Neoplasms
Transducers
Therapeutics
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute Myeloid Leukemia
Immune System
Lymphoma
Neoplasms

Keywords

  • Hematological malignancies
  • JAK inhibitors
  • JAK/STAT pathway

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies. / Mughal, Tariq I.; Girnius, Saulius; Rosen, Steven T.; Kumar, Shaji K; Wiestner, Adrian; Abdel-Wahab, Omar; Kiladjian, Jean Jacques; Wilson, Wyndham H.; Van Etten, Richard A.

In: Leukemia and Lymphoma, Vol. 55, No. 9, 2014, p. 1968-1979.

Research output: Contribution to journalArticle

Mughal, Tariq I. ; Girnius, Saulius ; Rosen, Steven T. ; Kumar, Shaji K ; Wiestner, Adrian ; Abdel-Wahab, Omar ; Kiladjian, Jean Jacques ; Wilson, Wyndham H. ; Van Etten, Richard A. / Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies. In: Leukemia and Lymphoma. 2014 ; Vol. 55, No. 9. pp. 1968-1979.
@article{19621ccb9d2b4d48b80f480a303fc7a6,
title = "Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies",
abstract = "Over the past decade, there has been increasing biochemical evidence that the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is aberrantly activated in malignant cells from patients with a wide spectrum of cancers of the blood and immune systems. The emerging availability of small molecule inhibitors of JAK and other signaling molecules in the JAK/STAT pathway has allowed preclinical studies validating an important role of this pathway in the pathogenesis of many hematologic malignancies, and provided motivation for new strategies for treatment of these diseases. Here, a round-table panel of experts review the current preclinical and clinical landscape of the JAK/STAT pathway in acute lymphoid and myeloid leukemias, lymphomas and myeloma, and chronic myeloid neoplasms.",
keywords = "Hematological malignancies, JAK inhibitors, JAK/STAT pathway",
author = "Mughal, {Tariq I.} and Saulius Girnius and Rosen, {Steven T.} and Kumar, {Shaji K} and Adrian Wiestner and Omar Abdel-Wahab and Kiladjian, {Jean Jacques} and Wilson, {Wyndham H.} and {Van Etten}, {Richard A.}",
year = "2014",
doi = "10.3109/10428194.2013.863307",
language = "English (US)",
volume = "55",
pages = "1968--1979",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies

AU - Mughal, Tariq I.

AU - Girnius, Saulius

AU - Rosen, Steven T.

AU - Kumar, Shaji K

AU - Wiestner, Adrian

AU - Abdel-Wahab, Omar

AU - Kiladjian, Jean Jacques

AU - Wilson, Wyndham H.

AU - Van Etten, Richard A.

PY - 2014

Y1 - 2014

N2 - Over the past decade, there has been increasing biochemical evidence that the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is aberrantly activated in malignant cells from patients with a wide spectrum of cancers of the blood and immune systems. The emerging availability of small molecule inhibitors of JAK and other signaling molecules in the JAK/STAT pathway has allowed preclinical studies validating an important role of this pathway in the pathogenesis of many hematologic malignancies, and provided motivation for new strategies for treatment of these diseases. Here, a round-table panel of experts review the current preclinical and clinical landscape of the JAK/STAT pathway in acute lymphoid and myeloid leukemias, lymphomas and myeloma, and chronic myeloid neoplasms.

AB - Over the past decade, there has been increasing biochemical evidence that the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is aberrantly activated in malignant cells from patients with a wide spectrum of cancers of the blood and immune systems. The emerging availability of small molecule inhibitors of JAK and other signaling molecules in the JAK/STAT pathway has allowed preclinical studies validating an important role of this pathway in the pathogenesis of many hematologic malignancies, and provided motivation for new strategies for treatment of these diseases. Here, a round-table panel of experts review the current preclinical and clinical landscape of the JAK/STAT pathway in acute lymphoid and myeloid leukemias, lymphomas and myeloma, and chronic myeloid neoplasms.

KW - Hematological malignancies

KW - JAK inhibitors

KW - JAK/STAT pathway

UR - http://www.scopus.com/inward/record.url?scp=84904037527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904037527&partnerID=8YFLogxK

U2 - 10.3109/10428194.2013.863307

DO - 10.3109/10428194.2013.863307

M3 - Article

VL - 55

SP - 1968

EP - 1979

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 9

ER -